X
[{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bonus BioGroup"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Bonus BioGroup"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Treatment with MesenCure reduced fluid in the lungs by 47% compared to untreated subjects, and significantly increased blood lymphocyte counts, which play a key role in fighting viruses.
Lead Product(s):
MesenCure
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 27, 2020
Details:
Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.
Lead Product(s):
Activated mesenchymal stromal cells
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 18, 2020